rdf:type |
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0004083,
umls-concept:C0005516,
umls-concept:C0025677,
umls-concept:C0178602,
umls-concept:C0178638,
umls-concept:C0311400,
umls-concept:C1280500,
umls-concept:C1704259,
umls-concept:C1705987,
umls-concept:C1709519
|
pubmed:issue |
10
|
pubmed:dateCreated |
2006-10-26
|
pubmed:abstractText |
To evaluate the contribution of metabolites (methotrexate [MTX] and folate polyglutamate [PG] levels) and pharmacogenetic biomarkers in the folate pathway to the effects of MTX in patients with rheumatoid arthritis not previously treated with this antifolate.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0004-3591
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3095-103
|
pubmed:dateRevised |
2007-6-7
|
pubmed:meshHeading |
pubmed-meshheading:17009228-Alleles,
pubmed-meshheading:17009228-Arthritis, Rheumatoid,
pubmed-meshheading:17009228-Dose-Response Relationship, Drug,
pubmed-meshheading:17009228-Enzymes,
pubmed-meshheading:17009228-Folic Acid Antagonists,
pubmed-meshheading:17009228-Humans,
pubmed-meshheading:17009228-Longitudinal Studies,
pubmed-meshheading:17009228-Methotrexate,
pubmed-meshheading:17009228-Middle Aged,
pubmed-meshheading:17009228-Multivariate Analysis,
pubmed-meshheading:17009228-Pharmacogenetics,
pubmed-meshheading:17009228-Polymorphism, Genetic,
pubmed-meshheading:17009228-Prospective Studies,
pubmed-meshheading:17009228-Pteroylpolyglutamic Acids,
pubmed-meshheading:17009228-Severity of Illness Index
|
pubmed:year |
2006
|
pubmed:articleTitle |
Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
|
pubmed:affiliation |
Prometheus, San Diego, California, USA.
|
pubmed:publicationType |
Journal Article
|